IOP Eye Pressure: What It Is and Its Link to Glaucoma

Intraocular pressure, or IOP, is the fluid pressure inside your eye, and it is the single most important modifiable risk factor for glaucoma. But the relationship between the two is not as straightforward as “high pressure equals disease.” Some people with elevated IOP never develop glaucoma, while others lose vision despite pressures that look perfectly normal on a standard exam. Understanding what IOP actually is, how it behaves throughout the day, and why it matters for the optic nerve helps make sense of why eye doctors treat it so seriously and why a single pressure reading never tells the whole story.

How Fluid Creates Pressure Inside the Eye

Your eye is not hollow. It is filled with a clear fluid called aqueous humor that circulates through the front portion of the eye, delivering nutrients to the lens and cornea and carrying waste away. This fluid is produced continuously by a structure called the ciliary body, located behind the iris. Three processes contribute to its formation: diffusion, ultrafiltration, and active secretion, with active secretion doing most of the work.¹ The fluid then flows forward through the pupil, bathes the front chamber of the eye, and drains out through specialized exit channels.

IOP is determined by the balance between how fast aqueous humor is produced and how fast it drains away. Think of a sink with the tap running: the water level depends on both the flow rate and how quickly the drain handles it. In the eye, the main drain is the trabecular meshwork, a sieve-like tissue in the angle where the iris meets the cornea. A second, smaller route called the uveoscleral pathway handles a portion of outflow and appears to serve as a backup when the primary route gets congested.² Most cases of elevated IOP trace back to increased resistance in the trabecular meshwork rather than overproduction of fluid.³

How Eye Pressure Is Measured

The standard method for measuring IOP is Goldmann applanation tonometry, which involves gently flattening a tiny area of the cornea and measuring the force required. It has been the clinical gold standard for decades and remains the recommended technique for guiding glaucoma diagnosis and management.⁴ You have probably experienced a version of this during a routine eye exam, either with a blue-light device pressed briefly against your numbed cornea or with a puff-of-air tonometer that estimates pressure without contact.

A commonly cited “normal” range is roughly 10 to 21 mmHg, but that number comes with important caveats. One of the biggest is corneal thickness. Goldmann tonometry was calibrated for an average cornea, so if your cornea is thicker than average, the instrument may overestimate your true IOP, and if it is thinner, it may underestimate it. Studies consistently show a positive relationship between corneal thickness and measured IOP readings.⁵ This means people with thin corneas can have glaucoma despite pressure readings that look reassuringly “normal,” while people with thick corneas can show elevated readings without any disease at all.⁶

What makes corneal thickness particularly tricky is that it appears to be an independent risk factor for glaucoma, not just a measurement artifact. A large population-based study found that people with thin corneas had a higher prevalence of open-angle glaucoma at every level of IOP, and simply applying a mathematical correction formula to “adjust” IOP for thickness did not eliminate that relationship.⁷ In other words, thin corneas seem to signal something about overall eye vulnerability that goes beyond just making the tonometer read low.

How Pressure Damages the Optic Nerve

Glaucoma is fundamentally a disease of the optic nerve, the cable that carries visual information from the retina to the brain. The damage happens at a specific bottleneck called the lamina cribrosa, a collagen-rich mesh at the back of the eye through which all nerve fibers must pass. When IOP rises, it creates mechanical strain on this structure. That strain disrupts axonal transport within the nerve fibers, triggers remodeling of the surrounding connective tissue, and ultimately causes retinal ganglion cells to die.⁸ These ganglion cells are the neurons whose axons form the optic nerve, so when they die, vision is permanently lost.

The damage is not simply a matter of pressure exceeding some threshold. Research shows that both the nerve head and the retina contain cells that act as mechanical sensors, responding to strain over time. Before ganglion cells actually die, they undergo changes in how they respond to growth-supporting signals and in their physical shape.⁹ This slow, progressive injury is why glaucoma typically steals peripheral vision first and why many people do not notice anything wrong until significant damage has already occurred.

The Structural Side of Vulnerability

Not every optic nerve responds to the same IOP the same way, and part of the reason lies in the physical properties of the eye’s supporting structures. Computational and experimental studies show that the amount the lamina cribrosa deforms under pressure depends on a complex mix of factors, including the thickness and stiffness of the surrounding sclera (the white of the eye) and the properties of the lamina itself.¹⁰ In human donor eyes, researchers have confirmed that the deformation of the lamina and the adjacent sclera interact with each other, meaning the overall strain the nerve fibers experience depends on how both tissues behave together.¹¹

This helps explain why two people with identical IOP readings can have very different outcomes. One person’s optic nerve head may be biomechanically resilient, while another’s may deform more readily under the same pressure. Some researchers have even explored artificially stiffening the sclera around the optic nerve to protect the lamina cribrosa from pressure-induced deformation, though this remains experimental.¹²

Normal-Tension Glaucoma

Perhaps the strongest evidence that IOP alone does not explain glaucoma is normal-tension glaucoma, a form of the disease in which all the hallmarks of glaucoma are present, including optic nerve damage and visual field loss, but IOP measurements consistently stay below 21 mmHg.¹³ The condition accounts for a substantial share of all open-angle glaucoma cases, and it is particularly common in East Asian populations.

The leading explanations for normal-tension glaucoma revolve around vascular insufficiency. Conditions that reduce blood flow to the optic nerve, including low blood pressure (especially at night), migraine, and Raynaud’s phenomenon, are commonly associated with it.¹³ Overly aggressive treatment of systemic hypertension, which pushes blood pressure too low, is also flagged as a contributor. In these scenarios, the optic nerve is vulnerable not because pressure is high but because blood supply is inadequate, even to handle normal pressure loads. Lowering IOP still helps slow progression in many of these patients, but it is often not sufficient on its own.

Blood Flow and Ocular Perfusion Pressure

The concept that ties IOP to blood supply is ocular perfusion pressure, essentially the difference between your blood pressure and your eye pressure. When perfusion pressure is low, whether because blood pressure drops or IOP rises, the optic nerve gets less blood flow. A systematic review and meta-analysis found that patients with open-angle glaucoma had lower perfusion pressure than healthy controls, and this relationship was strongest in patients whose IOP was already elevated.¹⁴ Interestingly, the trend was not significant in normal-tension glaucoma patients, suggesting different mechanisms may dominate in that subtype.

Longitudinal data from clinical trials reinforce this picture. Patients with low perfusion pressure at baseline progressed faster, with roughly a 40 to 55 percent increased risk of worsening compared to those with healthier perfusion. A history of cardiovascular disease also predicted faster progression among patients with higher baseline IOP.¹⁵ Glaucoma patients as a group show lower perfusion pressure and reduced blood flow velocity in the arteries supplying the retina compared to healthy individuals.¹⁶

Ocular Hypertension and the Case for Early Treatment

When IOP is elevated above the normal range but there is no detectable optic nerve damage or visual field loss, the condition is called ocular hypertension. Not everyone with ocular hypertension will develop glaucoma, but the risk is real enough that clinicians often recommend close monitoring and sometimes preventive treatment. A meta-analysis of randomized controlled trials found that lowering IOP in people with ocular hypertension roughly halved the risk of progressing to glaucoma, and estimated that treating about 12 patients would prevent one case of visual field damage or optic disc change within five years.¹⁷

This finding is one of the strongest pieces of evidence that elevated IOP is not merely a marker of glaucoma but a direct cause that, when reduced, slows or prevents the disease. That said, the decision about when to start treatment involves weighing the magnitude of IOP elevation, the presence of other risk factors like thin corneas or a family history, and the patient’s age and overall health.

Why Your Eye Pressure Changes Throughout the Day

IOP is not a fixed number. It fluctuates over a 24-hour cycle, and these fluctuations may matter for glaucoma risk independently of any single measurement. A large population-based study that tracked healthy subjects around the clock found that most people’s IOP peaked in the very early morning hours, around 3:50 AM, with about half showing a clear nocturnal peak pattern.¹⁸ About one in six had a daytime peak, and the rest showed no clear pattern. The average swing was modest in healthy eyes, but in glaucoma patients the fluctuations can be larger and more erratic.

The clinical implication is that a single daytime office reading can miss overnight spikes. This is one reason some researchers are excited about continuous monitoring technologies. Smart contact lenses embedded with sensors and wireless communication are being developed to track IOP in real time, potentially catching fluctuations that standard office visits would never detect.¹⁹ These are not yet in routine clinical use, but the technology is advancing rapidly.

Acute Angle-Closure Glaucoma

While most glaucoma develops slowly over years, acute angle-closure glaucoma is a medical emergency. It occurs when the drainage angle between the iris and cornea suddenly closes off, trapping aqueous humor and causing IOP to spike dramatically. Symptoms include severe eye pain, headache, nausea, blurred vision, and seeing halos around lights. Certain eye anatomies are more prone to this, particularly people with naturally shallow anterior chambers, which is more common in older adults, women, and people of East Asian descent. The incidence in Europe is roughly 2 to 4 cases per 100,000 people per year, but the consequences of delayed treatment are severe: without rapid pressure reduction, permanent vision loss can occur within hours.²⁰

Treatment focuses on bringing the pressure down fast, typically with medications and then laser iridotomy, which creates a small hole in the iris to restore fluid flow. If you experience sudden severe eye pain with vision changes, especially if accompanied by nausea, get emergency eye care immediately.

Everyday Activities That Affect IOP

Certain body positions and activities produce short-term IOP changes that can be surprisingly large. Inverted yoga poses are the best-studied example. In one study, the downward-facing dog position raised IOP from about 17 mmHg to nearly 29 mmHg within two minutes of holding the pose.²¹ Full headstands roughly doubled baseline IOP.²² These spikes return to normal fairly quickly once you come out of the position, but for someone with glaucoma or borderline IOP, frequent and prolonged inversions could be problematic.

Not all yoga affects IOP the same way. A meta-analysis found that certain slow breathing techniques and focused gazing exercises actually lowered IOP in glaucoma patients, while inversion poses caused the rapid increases described above.²³ Other common IOP-raising activities include playing high-resistance wind instruments, heavy weightlifting with breath-holding, wearing tight neckties, and sleeping face-down. None of these are proven to cause glaucoma on their own, but if you already have the disease or are at high risk, it is worth discussing them with your eye doctor.

Genetics and IOP

Your baseline IOP has a genetic component. Research using polygenic risk scores, which aggregate the effects of many small genetic variants, has shown that people in the highest genetic risk group for IOP had maximum recorded pressures about 1.7 mmHg higher than those in the lowest risk group. That may not sound like much, but higher genetic risk was also associated with being diagnosed about 3.7 years younger, having more affected family members, and being 50 percent more likely to need surgery for their glaucoma.²⁴ These findings suggest that the genetic architecture behind IOP level also influences disease severity and treatment burden, not just whether the number on the tonometer runs a little high.

How IOP Is Lowered

Because IOP remains the only modifiable risk factor with strong trial evidence behind it, virtually all current glaucoma treatment focuses on bringing it down. The first-line approach is medicated eye drops. Prostaglandin analogues, which increase fluid outflow through the uveoscleral pathway, are the most commonly prescribed class. Other drop categories work by either reducing fluid production or opening the trabecular meshwork. Newer agents include Rho kinase inhibitors and nitric oxide donors, both of which target outflow resistance through different cellular mechanisms.²⁵

When drops alone are not enough, or when patients struggle with adherence, laser and surgical options come into play. Selective laser trabeculoplasty uses short pulses of laser energy to stimulate the trabecular meshwork and improve drainage. It works by targeting pigmented cells in the meshwork, triggering a biological response that opens up outflow.²⁶ It is increasingly used as a first-line treatment itself, not just as a fallback after drops fail. For more advanced disease, surgical procedures range from micro-invasive glaucoma surgery (MIGS) to traditional trabeculectomy, which creates a new drainage channel. Trabeculectomy generally achieves lower IOP and greater medication reduction than MIGS, but involves a longer recovery and higher risk of complications.²⁷

Beyond Pressure Lowering

The fact that some patients continue to lose vision despite well-controlled IOP has driven interest in neuroprotection: therapies aimed at keeping retinal ganglion cells alive through mechanisms that have nothing to do with fluid pressure. The idea is to intervene in the cell death process itself, targeting the pathways that lead to ganglion cell loss regardless of what triggered them.²⁸ Candidates under investigation include agents that reduce oxidative stress, block toxic neurotransmitter buildup, and enhance mitochondrial function within the nerve cells.

No neuroprotective drug has yet been approved specifically for glaucoma, and proving that one works is harder than it sounds. You need large trials running for years, with sensitive enough imaging to detect whether nerve fiber loss is genuinely slower in the treated group. Still, the search continues because the need is clear: even with excellent IOP control, a subset of patients progresses, and for them the answer has to lie somewhere other than pushing the pressure number lower.